Bronchial asthma
Conditions
Interventions
None listed
Sponsors
Japanese Red Cross Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with bronchial asthma according to general allergy guideline 2016 2) Patients with bronchial asthma using high-dose inhaled corticosteroids and long-acting beta 2 agonists 3) Patients who obtain written consent regarding the participation of this study
Exclusion criteria
Exclusion criteria: 1) Patients using a body defibrillator such as a pacemaker or ICD 2) Patients who have previously received bronchial thermoplasty (BT) 3) Patients with severe complications such as heart disease, liver disease or kidney failure 4) Patients with respiratory infection, blood coagulation disorder 5) Patients who had exacerbation of asthma or dose change of oral corticosteroids in the past 14 days 6) Patients who can not use drugs required for bronchoscopic procedures such as lidocaine, atropine, benzodiazepine type anxiolytic drugs 7) Patients with bronchial asthma-COPD overlap syndrome (ACOS) 8) Other patients judged unsuitable as subjects by doctor's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of adverse events of Grade 3 or higher onset occurring within 90 days after the final treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence rate of adverse events of Grade 1 or higher after each treatment 2. Asthma control after each treatment (ratio of number of strokes per week, rate of unscheduled outpatient visits in 1 week (including emergency outpatient visit)) 3. Drug reduction effect after final treatment 4. Change in bronchial wall thickening after each treatment 5. Each treatment time 6. Activation count for each treatment 7. Adverse events of Grade 1 or higher from primary evaluation to 1 year after the last treatment | — |
Countries
Japan
Contacts
Public ContactTakehiro Izumo
Japanese Red Cross Medical Center Respiratory Medicine
Outcome results
None listed